The Top 5 Articles from ACR Convergence 2020

Here are the top 5 biosimilar articles from the American College of Rheumatology (ACR) Convergence 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

The American College of Rheumatology’s (ACR) Convergence 2020 was the annual meeting of the ACR. This year, due to the pandemic, the meeting was hosted virtually from November 5 to 9. During the conference, a number of study findings were presented on biosimilars used to treat rheumatic diseases. Here are the top 5 biosimilar articles from ACR Convergence 2020.

Number 5: One study of multiple biosimilar switches for patients with a variety of rheumatic musculoskeletal diseases demonstrated a high rate of patient retention and no major changes in disease activity or function.

Number 4: In a study of the use of infliximab biosimilars among patients with gastrointestinal and rheumatologic conditions, investigators found high adherence.

Number 3: Investigators presented evidence of what they say are successful, first-time tests of a multibiomarker disease activity score in patients with rheumatoid arthritis.

Number 2: Separate studies, including one on application methods for Celltrion’s adalimumab biosimilar candidate (CT-P17), were reported at the ACR Convergence 2020.

Number 1: Poster presentations at the meeting shed light on performance of Pfizer’s and Celltrion’s versions of adalimumab biosimilars.

To read all of these articles and more, visit